- Tytuł:
- Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience
- Autorzy:
-
Buraczewska, Agnieszka
Kardas, Joanna
Młot, Beata
Solarek, Wojciech
Waśko-Grabowska, Anna - Powiązania:
- https://bibliotekanauki.pl/articles/1062936.pdf
- Data publikacji:
- 2017
- Wydawca:
- Medical Education
- Tematy:
-
cabozantinib
hypothyroidism
renal cell carcinoma - Opis:
- Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabozantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
- Źródło:
-
OncoReview; 2017, 7, 3; 121-125
2450-6125 - Pojawia się w:
- OncoReview
- Dostawca treści:
- Biblioteka Nauki
Artykuł